Ono Pharma PROSPECT Study for PCNSL Patients
Ono Pharma is actively recruiting patients with Primary Central Nervous System Lymphoma (PCNSL) for the PROSPECT Study. PROSPECT is an open-label, Phase II study evaluating the evaluating the efficacy, safety, and pharmacokinetics of an investigational oral medicine called Tirabrutinib, a Bruton’s Tyrosine Kinase inhibitor.
Current treatment options for PCNSL are limited, and there are no medications approved specifically for the treatment of PCNSL in the United States. New treatment options are needed to improve the prognosis for those with PCNSL. The PROSPECT study is a clinical trial to evaluate an investigational oral medicine called Tirabrutinib in patients with PCNSL. About 112 participants will be enrolled in the Phase II PROSPECT study in the United States.
- Trials & Studies
- New Research
- Patient & Caregiver Resources
- Disease Information
- Meetings & Events
- And More!
Scan or click the QR code to download the App now!